Roy F. Waldron
Direktor/Vorstandsmitglied bei Starton Therapeutics, Inc.
Profil
Roy F.
Waldron is currently a Director at Starton Therapeutics, Inc. and an Independent Director at HWEL Holdings Corp.
He previously worked as the Chief Intellectual Property Counsel & Senior VP at Pfizer Inc. Waldron received his undergraduate degree from Dartmouth College, his doctorate from Yale University, and his graduate degree from New York University School of Law.
Aktive Positionen von Roy F. Waldron
Unternehmen | Position | Beginn |
---|---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Direktor/Vorstandsmitglied | 01.05.2019 |
Ehemalige bekannte Positionen von Roy F. Waldron
Unternehmen | Position | Ende |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - |
Ausbildung von Roy F. Waldron
New York University School of Law | Graduate Degree |
Yale University | Doctorate Degree |
Dartmouth College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
PFIZER, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |